Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Decitabine/Tetrahydrouridine + Pembrolizumab in Advanced Thoracic Cancers
NCT03233724Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Apr 2018
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of decitabine and tetrahydrouridine in non-small cell lung cancer (NSCLC), esophageal carcinoma and malignant pleural mesothelioma (MPM), sponsored by National Cancer Institute. Primary endpoints: Overall Response Rate, Maximum Tolerated Dose of Decitabine at 6 weeks and 1 more. Started Apr 2018; status: terminated.
02
Drugs
decitabinetetrahydrouridine
03
Conditions
non-small cell lung cancer (NSCLC)esophageal carcinomamalignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT03233724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03233724.